VERVE-102

N/A

Report date: 2025/12/08 17:14:04

Base Information

Drug NameVERVE-102
Drug Alias NamePCSK9 Editor (VERVE-102)VERVE-102
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPRCell and gene therapy > Gene therapy > LNP
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaAtherosclerosisCoronary Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVerve Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVerve Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaAtherosclerosisCoronary Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A